Skip to Content

Tag Archives: WIN

Pfizer: A Shift in the Wind

More and more, it’s looking as if the worst is over for the pharmaceutical industry — and especially for the 800-pound gorilla, Pfizer (NYSE: PFE). Last Friday, a Food & Drug Administration advisory panel voted overwhelmingly (31-1) to recommend keeping PFE’s painkiller Celebrex on the market. The same panel also voted, by a slimmer (17-13) margin, to advise the FDA to allow continued sales of Pfizer’s other controversial cox-2 painkiller, Bextra.

October 2004 Issue & Supplement

In this month’s visit, we’ll take our strategy a step further. Among our World-Class Franchises, we’re swapping out of a lower-yielding stock into another that will double our dividend income. Plus, I’m looking for our newest selection to deliver growth of up to 60% in its share price over the next three years.